Free Trial

BeyondSpring (BYSI) Competitors

BeyondSpring logo
$1.70 +0.06 (+3.66%)
As of 11:04 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BYSI vs. CABA, AVTE, VTYX, PRQR, OGI, RENB, TLSA, AVIR, IMRX, and JMAC

Should you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Cabaletta Bio (CABA), Aerovate Therapeutics (AVTE), Ventyx Biosciences (VTYX), ProQR Therapeutics (PRQR), Organigram Global (OGI), Lunai Bioworks (RENB), Tiziana Life Sciences (TLSA), Atea Pharmaceuticals (AVIR), Immuneering (IMRX), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry.

BeyondSpring vs. Its Competitors

Cabaletta Bio (NASDAQ:CABA) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

BeyondSpring's return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Cabaletta BioN/A -92.11% -74.08%
BeyondSpring N/A N/A N/A

40.3% of BeyondSpring shares are held by institutional investors. 11.3% of Cabaletta Bio shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cabaletta Bio has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.

BeyondSpring has higher revenue and earnings than Cabaletta Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cabaletta BioN/AN/A-$115.86M-$2.71-1.04
BeyondSpring$1.75M39.18-$11.12MN/AN/A

In the previous week, Cabaletta Bio had 13 more articles in the media than BeyondSpring. MarketBeat recorded 16 mentions for Cabaletta Bio and 3 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 0.83 beat Cabaletta Bio's score of 0.49 indicating that BeyondSpring is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cabaletta Bio
1 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
BeyondSpring
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cabaletta Bio currently has a consensus target price of $13.44, suggesting a potential upside of 375.91%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Cabaletta Bio is more favorable than BeyondSpring.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cabaletta Bio
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
BeyondSpring
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

BeyondSpring beats Cabaletta Bio on 7 of the 13 factors compared between the two stocks.

Get BeyondSpring News Delivered to You Automatically

Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BYSI vs. The Competition

MetricBeyondSpringMED IndustryMedical SectorNASDAQ Exchange
Market Cap$68.56M$3.39B$6.06B$10.57B
Dividend YieldN/A2.30%5.73%4.80%
P/E RatioN/A22.7385.0727.47
Price / Sales39.18268.36518.67200.70
Price / CashN/A46.9537.5761.53
Price / Book-4.5910.5412.336.87
Net Income-$11.12M-$52.58M$3.32B$276.69M
7 Day Performance-5.03%0.74%0.70%0.70%
1 Month Performance-9.09%15.64%10.27%8.83%
1 Year Performance-31.73%18.08%74.67%36.06%

BeyondSpring Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BYSI
BeyondSpring
N/A$1.70
+3.7%
N/A-34.1%$68.56M$1.75M0.0080News Coverage
CABA
Cabaletta Bio
2.9985 of 5 stars
$2.89
+16.1%
$13.44
+365.2%
-32.0%$264.32MN/A-1.0750High Trading Volume
AVTE
Aerovate Therapeutics
N/A$9.09
+0.1%
N/A-87.9%$263.47MN/A-3.0420News Coverage
Gap Down
High Trading Volume
VTYX
Ventyx Biosciences
1.9259 of 5 stars
$3.65
-1.6%
$7.50
+105.5%
+56.0%$260.28MN/A-2.1730
PRQR
ProQR Therapeutics
2.1452 of 5 stars
$2.46
+7.4%
$8.00
+225.2%
+35.9%$258.82M$20.46M-5.35180
OGI
Organigram Global
1.1768 of 5 stars
$1.90
-1.0%
N/A+7.3%$255.25M$117.47M38.01860
RENB
Lunai Bioworks
0.7084 of 5 stars
$1.54
+21.7%
N/A-72.0%$250.24MN/A-2.0020Positive News
Gap Down
TLSA
Tiziana Life Sciences
0.6949 of 5 stars
$2.14
+0.5%
N/A+130.4%$250.06MN/A0.008
AVIR
Atea Pharmaceuticals
1.8626 of 5 stars
$3.14
+1.0%
$6.00
+91.1%
-11.0%$249.19MN/A-1.9570
IMRX
Immuneering
3.8464 of 5 stars
$5.96
-2.9%
$16.40
+175.2%
+198.0%$247.76M$320K-3.1560Positive News
JMAC
Maxpro Capital Acquisition
N/A$18.43
flat
N/AN/A$247.52MN/A0.002,021

Related Companies and Tools


This page (NASDAQ:BYSI) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners